|
 Academic Year: |
2014/5 |
| Owning Department/School: |
Department of Pharmacy & Pharmacology |
| Credits: |
6 |
| Level: |
Masters UG & PG (FHEQ level 7) |
| Period: |
Semester 2 |
| Assessment Summary: |
CW 25%, EX 75% |
| Assessment Detail: |
|
| Supplementary Assessment: |
Like-for-like reassessment (where allowed by programme regulations) |
| Requisites: |
Before taking this unit you must take PA10281 and take PA20294 and take PA30287 |
| Description: |
Aims: The aims of this unit are to acquire an understanding of (a) recent advances on therapeutic drug monitoring, (b) variability in ADME processes and (c) individualized drug therapy based on pharmacokinetic, pharmacodynamic and pharmacogenomic principles. Learning Outcomes: On successful completion of this unit, the student should be able to: (a) critically evaluate elements of clinical pharmacokinetics and apply them to therapeutic drug monitoring and drug therapy; (b) predict and analyze the effect of variability (disease, genetics, adherence, age etc.) on a therapy outcome and (c) critically analyse and discuss scientific pharmacokinetic data and apply it to drug therapy. Skills: Scientific skills: Data analysis and clinical interpretation. (T/F/A) Study skills, finding and handling information (T/F/A) Working with others (F). Problem solving (T/F/A). Communication skills (F) Content: This unit focuses on clinical pharmacokinetics, sources of variability in drug therapy and therapeutic drug monitoring. This will include: (a) the scientific basis for therapeutic drug monitoring and individualized therapy. Application to relevant drugs in practice and recent advances in the field. (b) Variability in the ADME processes caused by disease, age, obesity, interactions, life style and genetics. (c) Use of pharmacokinetics and PK parameters to interpret drug variability and individualize therapy. |
| Programme availability: |
PA40253 is Optional on the following programmes:Department of Pharmacy & Pharmacology
|